April 11, 2018Open Access
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Structured PICO
Does sacubitril/valsartan reduce the rate of eGFR decrease and improve cardiovascular outcomes compared to enalapril in patients with heart failure?
P
Population
Patients with heart failure, including those with chronic kidney disease
I
Intervention
Sacubitril/valsartan
C
Comparator
Enalapril
O
Outcome
Rate of decrease in eGFR and cardiovascular outcomes
Sacubitril/valsartan provides renoprotective effects by slowing eGFR decline while improving cardiovascular outcomes in heart failure patients compared to enalapril.
Abstract
Compared with enalapril, sacubitril/valsartan led to a slower rate of decrease in the eGFR and improved cardiovascular outcomes, even in patients with chronic kidney disease, despite causing a modest increase in UACR.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
K
Kevin Damman
Heart Failure & Transplant
M
Mauro Gori
Heart Failure & Transplant
Brian Claggett
Heart Failure & Transplant
Journals
JACC Heart Failure
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
Actions
Institutions
Brigham and Women's Hospital
Imperial College London
University of Groningen
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...